Iridex posts Q4 2024 revenue $12.7M, achieves positive adjusted EBITDA; net loss narrows to $0.8M

IRIDEX CORP

Q4 revenue $12.7M vs $12.5M YoY; adjusted EBITDA positive $0.4M vs ($2.0M) loss prior year.
Net loss improved to $0.8M ($0.05/share) from $3.0M ($0.18/share); operating expenses down 24% to $6.1M.
Cyclo G6 product family revenue $3.3M (+9% YoY); retina product revenue $7.3M (-3%).
Cash $2.4M at year-end; subsequent $10M strategic investment from Novel Innovations at $2.00/share.
Guidance: expects cash flow breakeven and positive adjusted EBITDA in 2025 on FY revenue consistent with 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.